Oncimmune’s proprietary EarlyCDT® cancer detection tests are based on the presence in the blood of autoantibodies against specific tumour associated antigens that have the potential to detect cancer up to four years earlier than other methods and can be applied to a very wide range of solid tumour types.

When a tumour is present, it produces abnormal proteins (known as antigens). Cancer antigens are different to normal antigens so the body reacts to these antigens by producing autoantibodies. These autoantibodies, which can arise in the earliest stages of cancer and have been shown to be present at all stages, are produced in sufficient quantities to be measured in an individual’s blood using a simple blood test.

Oncimmune’s EarlyCDT®Lung test has undergone extensive scientific and clinical validation studies. More than 120,000 patient samples were run to validate its technical and clinical performance to 2012. Since then over 150,000 commercial tests have also been run.

EarlyCDT®Lung is being used in what is generally acknowledged to be the largest randomised trial for the early detection of lung cancer using biomarkers ever conducted; the National Health Service (NHS) Scotland ECLS study of 12,000 high-risk smokers.1

1 Sullivan FM, Farmer E, Mair FS et al. Detection in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer using the EarlyCDT®-Lung Test (ECLS): study protocol for randomized controlled trial. BMC Cancer 2017;17:187.


Electronic versions of the materials you are seeking to access are being made available on this website by Oncimmune Holdings plc (the “Company”).

These materials are not directed to nor are they intended for access by persons located or resident in the United States, Australia, Canada, South Africa, Japan or any other jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.

None of the securities of Company discussed or referred to in the materials you are seeking to access have been registered under the US Securities Act or 1933, as amended (the “Securities Act”) and may not be offered, sold, pledged or otherwise transferred except (1) in an offshore transaction meeting the requirements of Rule 903 or Rule 904 of Regulation S under the Securities Act, (2) pursuant to an effective registration statement under the Securities Act, or (3) pursuant to an available exemption from the registration requirements of the Securities Act, in each case in accordance with all applicable securities laws.

By clicking the “SUBMIT” button below you confirm that you (1) have read and understood the information set out above, (2) agree to be bound by its terms, (3) are not located in the United States and do not have a registered address in, and are not resident or located in, Australia, Canada, South Africa or Japan and (4) are permitted under applicable law and regulation to proceed to the following parts of this website.

Please click on the button below to confirm that you have read, understood and agree with the disclaimer above.

Yes, I accept No, I don't accept